The Open Payments Expansion Act proposes to amend Title XI of the Social Security Act, specifically expanding the existing Open Payments program. This legislation would require pharmaceutical and device manufacturers , as well as applicable group purchasing organizations, to publicly disclose financial transfers made to patient advocacy organizations . These disclosures would include both direct payments and indirect transfers of value where the manufacturer directs a third party to make the payment. Starting March 31, 2027, and annually thereafter, manufacturers would submit details such as the name of the patient advocacy organization and the amount of the covered payment to the Secretary. A patient advocacy organization is defined as a 501(c)(3) entity providing education, advocacy, or support for patients and caregivers, or assisting vulnerable individuals affected by medical conditions. This measure aims to enhance transparency by revealing financial relationships between industry and patient groups.